Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996877 · ClinicalTrials.gov registry record
Outcomes of Surgically Ineligible Patients With Multivessel CAD
A clinical trial, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- 750
- Enrollment target
NCT02996877: Completed study, sponsored by Saint Luke's Health System.
NCT02996877 is a clinical trial that has completed, run by Saint Luke's Health System. The registered enrollment target is 750 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996877 has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
The OPTIMUM registry is a minimal risk observational study that uses a prospective cohort design to follow patients who have multivessel or left main coronary artery disease ("surgical anatomy" according to ACC/AHA Appropriateness Criteria for PCI12) and are deemed ineligible for coronary artery bypass surgery. It is anticipated that 20 sites will be selected to participate in the registry from a national network of leading centers across the United States with recognized expertise in both complex PCI and coronary artery bypass surgery. We will invite leading cardiac centers, as defined by US News and World reports rankings for heart care. Additional sites may be added to meet the target enrollment goal.
Primary Outcome
Patients will be followed with phone calls at 30 days.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2020-06-22 |
What the finished NCT02996877 record still lists
NCT02996877 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02996877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02996877 about?
NCT02996877 is a clinical study titled "Outcomes of Surgically Ineligible Patients With Multivessel CAD". The OPTIMUM registry is a minimal risk observational study that uses a prospective cohort design to follow patients who have multivessel or left main coronary artery disease ("surgical anatomy" according to ACC/AHA Appropriateness Criteria for PCI12) and are deemed ineligible for coronary artery byp...
What is the current status of trial NCT02996877?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2016-12-15. Estimated completion is 2020-06-22.
Who is sponsoring clinical trial NCT02996877?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI